Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Open-label, Active-controlled Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of Hepenofovir Fumarate Tablets in Patients With CHB

NCT06122454 is registered in ClinicalTrials.gov with Xi'an Xintong Pharmaceutical Research Co.,Ltd. as lead sponsor.

NCT NCT06122454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06122454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Open-label, Active-controlled Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of Hepenofovir Fumarate Tablets in Patients With CHB
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 10, 2022
Completion date
December 30, 2024
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, pharmacokinetics, safety